

The information in the press release is intended for investors.

Bulletin from annual general meeting in Isofol Medical AB (publ) held on May 21, 2025

GOTHENBURG, May 21, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), held its annual general meeting (the “AGM”) today at which the following resolutions, in principal, were passed by the shareholders.

Adoption of income statements and balance sheets for 2024 and discharge from liability

The AGM resolved to adopt the income statements and balance sheets for the company for the financial year 2024. The members of the Board of Directors and the CEO were discharged from liability for the financial year 2024.

Allocation of earnings

The AGM resolved that no dividend shall be distributed for 2024 and that the company's unappropriated earnings shall be carried forward.

Election of board members and auditor, and fees to the Board of Directors and auditor

The AGM resolved that the number of members of the Board of Directors shall be five ordinary members without deputies and that the number of auditors shall be one registered accounting firm.

The AGM re-elected Jan-Eric Österlund, Alain Herrera, Helena Taflin, Lars Lind and Sten Nilsson as members of the Board of Directors. Jan-Eric Österlund was re-elected as chairman of the Board of Directors.

The registered accounting firm KPMG AB was re-elected as auditor of the company and it was noted that the authorised accountant Daniel Haglund will be auditor-in-charge.

The AGM resolved that fees to the chairman of the Board of Directors shall be paid with SEK 550,000, to each of the other members of the Board of Directors with SEK 250,000, to the chairman of the audit committee with SEK 125,000, to each of the other members of the audit committee with SEK 75,000, to the chairman of the remuneration committee with SEK 75,000 and to each of the other members of the remuneration committee with SEK 50,000.

The AGM resolved that the members of the Board of Directors (in addition to remuneration for expenses relating to travel and accommodation) domiciled in Europe, but outside the Nordic countries, shall receive a remuneration of SEK 7,500 per physical board meeting.

The AGM resolved that remuneration, for services rendered by the auditor of the company, shall be paid in accordance with approved invoice.

Determination of principles for the appointment of the nomination committee

The AGM resolved, in accordance with the nomination committee's proposal, that the principles for the appointment of the members of the nomination committee shall remain unchanged.

Approval of the Board of Directors' remuneration report

The AGM resolved, in accordance with the Board of Director's proposal, to approve the remuneration report for the financial year 2024.

Adoption of a long-term incentive program in the form of performance-based share rights for management and employees within the company and directed issue of warrants

The AGM resolved, in accordance with the Board of Directors' proposal, to implement a long-term incentive program in the form of performance-based share rights directed to senior executives and employees within Isofol. The motives behind the incentive program are, among other things, to contribute to higher motivation and commitment among the employees and strengthen the ties between the employees and the company.

Within the scope of the program, the Board of Directors will allocate rights to participants free of charge, entailing the right to, provided that certain conditions are met, receive performance shares. The vesting of the rights takes place over a period of three years calculated from the date of allocation of the rights.

Upon exercise of all 1,600,000 rights and 500,000 shares to hedge social security costs, the share capital will increase by a maximum of approximately SEK 64,260 and entail a maximum dilution corresponding to approximately 1.3 percent of the outstanding capital and number of votes in the company at the time of the issuance of the convening notice. To enable the incentive program, the AGM also resolved to issue a maximum of 2,100,000 warrants directed to the company.

Resolution to authorize the Board of Directors to resolve on new share issues

The AGM resolved to approve the Board of Director's proposal to authorize the Board of Directors, for the period until the end of the next Annual General Meeting, on one or more occasions and with or without deviation from the shareholders' preferential rights, to resolve on a new issue of shares.

The authorization may be utilized for issues of shares corresponding to a maximum of 20 percent of the registered share capital of the company at the time of the issue resolution. Deviation from the shareholders' preferential rights may be made in connection with future investments in the company's research studies where a deviation from the preferential rights is deemed to create increased value for all shareholders. If the Board of Directors resolves on an issue with deviation from the shareholders' preferential rights, the reason shall be that the Board of Directors shall be able to, in a quick and cost-effective manner, raise capital for research studies or for the purpose of attracting strategic and/or institutional investors.

For more information, please contact

Isofol Medical AB (publ)

Petter Segelman Lindqvist, CEO

E-mail: petter.s.lindqvist@isofolmedical.com

Phone: +46 (0)739 60 12 56

Margareta Hagman, CFO

E-mail: margareta.hagman@isofolmedical.com

Phone: + 46 (0)738 73 34 18

The information was submitted for publication, through the agency of the contact persons set out above, at 16:40 CEST on May 21, 2025.

About Isofol Medical AB (publ)

Isofol Medical AB (publ) works to improve the quality of life and prognosis for patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world's third most common cancer, where the medical need for better treatments is truly urgent. A phase Ib/II study is now being conducted with a new dosage regimen that are expected to optimize the effect of the drug candidate. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.

www.isofolmedical.com